Distinct Vascular Impacts of JAK Inhibitors on Endothelial Inflammation

Study Background and Research Question

Patients with rheumatoid arthritis (RA) exhibit a heightened risk of cardiovascular (CV) events, a phenomenon closely tied to chronic systemic inflammation and endothelial dysfunction. Proinflammatory cytokines—especially tumor necrosis factor (TNF) and interleukin-17A (IL-17A), the latter secreted by Th17 cells—synergistically drive the activation of endothelial cells (ECs), promoting cytokine release, expression of adhesion molecules, and procoagulant states. While JAK-STAT signaling is central to mediating immune and inflammatory signals from various cytokines, the impact of different Janus kinase inhibitors (JAKi) on endothelial health and thrombosis risk remains debated. This prompted Zavoriti and Miossec’s recent study (ACR Open Rheumatology 2025) to systematically compare the vascular effects of multiple JAK inhibitors—including tofacitinib citrate (CP-690550 citrate)—under conditions mimicking inflammatory stress relevant to RA.

Key Innovation from the Reference Study

The central innovation of Zavoriti and Miossec’s work lies in its direct comparison of the vascular and inflammatory effects of several clinically approved JAK inhibitors on human ECs exposed to TNF and IL-17A. By examining mediator release, adhesion molecule induction, procoagulant and anticoagulant pathway modulation, and apoptosis, the study provides a nuanced landscape of how JAK inhibitor specificity translates into divergent functional outcomes. Notably, it highlights that while all tested JAKi can dampen cytokine-driven inflammation, their effects on endothelial adhesion, coagulation, and cell viability are not uniform, with some agents (such as tofacitinib citrate) displaying distinct profiles at different concentrations.

Methods and Experimental Design Insights

The investigation utilized primary human vascular endothelial cells stimulated with TNF and IL-17A to induce an inflammatory phenotype characteristic of RA. Six JAK inhibitors—tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib—were tested at 1 and 10 μM concentrations. Key experimental endpoints included:

• Cytokine release: IL-6 and IL-8 measured by enzyme-linked immunosorbent assay (ELISA)
• Adhesion molecule expression: VCAM-1, ICAM-1, and E-selectin quantified by qRT-PCR
• Procoagulant/anticoagulant factors: Tissue factor and thrombomodulin gene expression analysis
• Apoptosis: Annexin V staining to quantify EC death

This multifaceted approach enabled the authors to dissect not only anti-inflammatory efficacy but also potential prothrombotic and cytotoxic consequences of each JAK inhibitor.

Core Findings and Why They Matter

The study’s findings offer a granular view into the complex vascular effects of JAK inhibition (reference study):

• Suppression of Inflammatory Cytokines: All JAK inhibitors reduced IL-6 release from inflamed ECs, confirming their broad anti-inflammatory activity. Notably, baricitinib and fedratinib uniquely decreased IL-8 overproduction, a chemokine implicated in leukocyte recruitment and vascular injury, at both tested concentrations.
• Adhesion Molecule Regulation: Tofacitinib citrate at 1 μM decreased ICAM-1 and E-selectin expression—key mediators of leukocyte adhesion and endothelial activation. However, at 10 μM, several JAKi (including tofacitinib) paradoxically enhanced VCAM-1 and ICAM-1 induction in the presence of TNF+IL-17A, suggesting a concentration-dependent effect that could impact vascular inflammation and thrombosis risk.
• Coagulation Pathway Modulation: Peficitinib and fedratinib consistently reduced tissue factor up-regulation at both concentrations, with ruxolitinib effective only at 1 μM. None of the JAK inhibitors prevented the TNF+IL-17A-driven downregulation of thrombomodulin, an anticoagulant protein, indicating limitations in their capacity to counteract prothrombotic shifts.
• Endothelial Cell Viability: Peficitinib and fedratinib induced significant EC apoptosis and cytotoxicity, whereas other JAK inhibitors—including tofacitinib citrate—did not, supporting their differential safety profiles for vascular health.

These data emphasize that even within the JAK inhibitor class, molecular selectivity and dosing critically shape the spectrum of vascular effects—an important consideration for both preclinical modeling and translational research in inflammatory disorder research and immune regulation.

Comparison with Existing Internal Articles

Internal literature provides further context for interpreting these findings. For example, "Distinct Vascular Effects of JAK Inhibitors in Endothelial Inflammation" echoes the importance of nuanced cytokine modulation and endothelial apoptosis differences among JAK inhibitors. Similarly, "Tofacitinib Citrate (CP-690550): Selective JAK3 Inhibition Unpacked" highlights the compound’s selectivity for JAK3 and its reproducibility in dissecting JAK-STAT pathway function. These internal resources reinforce the present study’s conclusion that selective Janus kinase 3 inhibitors like tofacitinib citrate offer both opportunities and caveats for probing immune and vascular responses in vitro.

Limitations and Transferability

While the study provides critical mechanistic insights, several limitations should be considered. First, experiments were restricted to primary human ECs in vitro, which may not fully recapitulate the complexity of in vivo vascular beds or the influence of systemic factors. The concentrations of JAK inhibitors tested (1 and 10 μM) may exceed physiologically relevant levels in some clinical contexts, raising questions about transferability to human dosing regimens. Additionally, the study did not address chronic exposure or the effects of JAK inhibition in co-culture or three-dimensional systems that better model vascular-immune interactions. Finally, the restricted focus on TNF and IL-17A, while highly relevant to RA, may not encompass all inflammatory drivers encountered in other autoimmune or cardiovascular contexts. Nevertheless, these in vitro findings provide a robust foundation for refining experimental models and underscore the need for careful titration and specificity when using JAK inhibitors in immune regulation research.

Protocol Parameters

• Tofacitinib citrate (CP-690550 citrate) concentration: 1 μM is effective for reducing ICAM-1 and E-selectin induction in inflamed ECs; higher concentrations (10 μM) may paradoxically enhance VCAM-1 and ICAM-1 expression according to the reference study.
• Cytokine stimulation: Use TNF (10 ng/mL) plus IL-17A (10 ng/mL) to induce robust endothelial inflammation and procoagulant response, per standard models.
• Apoptosis assessment: Quantify EC apoptosis using Annexin V staining 24 hours post-treatment to distinguish cytotoxic from non-cytotoxic JAK inhibitors.
• Readout timing: Measure cytokine release and adhesion molecule gene expression 6–24 hours after JAK inhibitor and cytokine co-treatment for optimal sensitivity.
• Compound handling: Prepare tofacitinib citrate stock in DMSO at ≥25 mg/mL and dilute freshly to working concentrations; avoid long-term storage of aqueous solutions (product information).

Research Support Resources

For researchers aiming to model JAK-STAT signaling, lymphocyte proliferation inhibition, or immune cell-endothelial interactions in vitro, Tofacitinib citrate (CP-690550 citrate) (SKU A4135) offers well-characterized selectivity and potency suitable for these workflows. Its established solubility and storage guidelines facilitate reliable experimental setup. Further technical insights and protocol recommendations can be found in internal resources such as "Applied Workflows with Tofacitinib Citrate in Immune Regulation". As always, compound concentrations and exposure conditions should be carefully optimized for each experimental context to balance efficacy and endpoint specificity.